Abstract
The most widely used mouse models for atherosclerosis are LDL receptor knockout (KO) mice and apolipoprotein E (apoE) KO mice fed standard chow diets or lipid-supplemented diets. Unfortunately, these do not usually exhibit myocardial infarction or other features of human cardiovascular disease such as occlusive coronary artery disease, cardiac dysfunction and/or reduced lifespan. Surgical models of myocardial infarction are successfully used for drug testing analyses during acute ischemia, but do not allow investigation of underlying mechanisms related to atherosclerotic coronary artery disease. Recently, experts in the pharmaceutical industry as well as some at the US Food and Drug Administration have identified inadequate animal models as being one of the major hurdles in drug discovery and development. There is an important need for additional well-characterized, genetically manipulable, small animal models that mimic many features of human coronary heart disease (CHD), which would provide investigators in academia and in the pharmaceutical industry with a better system to unravel the pathophysiology of atherosclerotic CHD and to evaluate preclinical drug candidates. Here we will review recently developed mouse models of occlusive CHD, focusing on mice lacking expression of the HDL receptor, SR-BI in the context of reduced expression of apoE.
Current Drug Targets
Title: Myocardial Infarction Following Atherosclerosis in Murine Models
Volume: 9 Issue: 3
Author(s): Bernardo L. Trigatti, Anne Braun and Attilio Rigotti
Affiliation:
Abstract: The most widely used mouse models for atherosclerosis are LDL receptor knockout (KO) mice and apolipoprotein E (apoE) KO mice fed standard chow diets or lipid-supplemented diets. Unfortunately, these do not usually exhibit myocardial infarction or other features of human cardiovascular disease such as occlusive coronary artery disease, cardiac dysfunction and/or reduced lifespan. Surgical models of myocardial infarction are successfully used for drug testing analyses during acute ischemia, but do not allow investigation of underlying mechanisms related to atherosclerotic coronary artery disease. Recently, experts in the pharmaceutical industry as well as some at the US Food and Drug Administration have identified inadequate animal models as being one of the major hurdles in drug discovery and development. There is an important need for additional well-characterized, genetically manipulable, small animal models that mimic many features of human coronary heart disease (CHD), which would provide investigators in academia and in the pharmaceutical industry with a better system to unravel the pathophysiology of atherosclerotic CHD and to evaluate preclinical drug candidates. Here we will review recently developed mouse models of occlusive CHD, focusing on mice lacking expression of the HDL receptor, SR-BI in the context of reduced expression of apoE.
Export Options
About this article
Cite this article as:
Trigatti L. Bernardo, Braun Anne and Rigotti Attilio, Myocardial Infarction Following Atherosclerosis in Murine Models, Current Drug Targets 2008; 9 (3) . https://dx.doi.org/10.2174/138945008783755566
DOI https://dx.doi.org/10.2174/138945008783755566 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alternatively Spliced Genes as Biomarkers for Schizophrenia, Bipolar Disorder and Psychosis: A Blood-Based Spliceome-Profiling Exploratory Study (Supplementry Table)
Current Pharmacogenomics and Personalized Medicine Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Intravascular Targeting of a New Anticoagulant Heparin Compound
Cardiovascular & Hematological Disorders-Drug Targets The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study
Current Vascular Pharmacology Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews Can We Move Forward After ADVANCE?
Vascular Disease Prevention (Discontinued) Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Analgesic Drug Discovery: Promising Future (Guest Editor: Anindya Bhattacharya)]
Current Pharmaceutical Biotechnology Nonfasting Hyperlipidemia and Cardiovascular Disease
Current Drug Targets Inflamm-Aging, Cytokines and Aging: State of the Art, New Hypotheses on the Role of Mitochondria and New Perspectives from Systems Biology
Current Pharmaceutical Design Development and Validation of a Stability-Indicating HPLC Method for the Assay of Carvedilol in Pure and Tablet Dosage Forms
Current Pharmaceutical Analysis Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry Novel Findings and Therapeutic Targets on Cardioprotection of Ischemia/ Reperfusion Injury in STEMI
Current Pharmaceutical Design